October 5, 2010 (Cincinnati, Ohio) - BioRx, a specialty pharmacy company, has received limited distribution rights from Baxter International Inc. for a new drug, GLASSIA™ Alpha 1-Proteinase Inhibitor (Human)], the first and only liquid, ready-to-use treatment for alpha-1 antitrypsin deficiency (AATD) in the United States. AATD is a genetic disorder that causes low levels of alpha 1-antitrypsin, resulting in emphysema. AATD is also referred to as “genetic” or “congenital” emphysema.

As a result of this limited distribution agreement, BioRx will also be added as a distributor of ARALAST NP, a similar product to Baxter’s first alpha-1 proteinase inhibitor (A1-Pi), ARALAST, originally launched in 2003. BioRx will begin stocking both GLASSIA and ARALAST NP this month.

On August 24, Baxter announced an agreement with Kamada LTD, the company that manufactures GLASSIA, for exclusive commercial rights to GLASSIA in the United States, Australia, New Zealand and Canada. The FDA approved GLASSIA, which is indicated for chronic augmentation and maintenance therapy in individuals with emphysema due to congenital deficiency of A1-PI, on July 1, 2010. For more about Baxter and GLASSIA, visit: http://www.baxter.com/press_room/press_releases/2010/08_24_10_glassia.html

“We congratulate Baxter on its acquisition of GLASSIA, said Eric Hill, vice president of BioRx. “BioRx is pleased to offer alpha-1 patients a unique formulation of alpha-1 proteinase inhibitor that may ease their therapy routine. Moreover, we are proud to enter the alpha-1 marketplace and be able to offer our commitment and support to the alpha-1 community.”

Larry Guiheen, president of Global BioPharmaceuticals for Baxter BioScience, said “Our agreement with Kamada broadens the therapeutic options available to alpha-1 patients and their treating physicians. Likewise, the addition of BioRx to our distribution channel extends the high-quality homecare choices available to the growing population of diagnosed alpha-1 patients.”

About GLASSIA™
Glassia is a unique, high purity, ready-to-use liquid alpha- 1 proteinase inhibitor that is indicated for chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha1-proteinase inhibitor, also known as alpha-1 antitrypsin deficiency (AATD). The product is produced using a patented, proprietary chromatographic purification method. Additional information is provided at www.myglassia.com.

About ARALAST NP
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of α1-PI with clinically evident emphysema. Additional information is provided at www.aralast.com.

About BioRx
Based in Cincinnati, Ohio, BioRx is one of the nation’s fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving the alpha-1 community, BioRx offers pharmacy, nursing and education services to patients with bleeding disorders, immune deficiencies, autoimmune disorders, hereditary angioedema, and nutritional/digestive disorders. The company’s clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.net.

About Baxter
Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Additional information is available at www.baxter.com.

Contact:
Judith Cline>
Tel: 866.44.BIORX>
Email: jcline@biorx.net